← FDA DRUG APPROVALS

FDA ANDA · ANDA078226

AMLODIPINE BESYLATE

Sponsor: ZYDUS PHARMS USA

APPLICATION
ANDA078226
TYPE
ANDA
ORIGINAL APPROVAL
2007-07-09
LATEST ACTION
2018-03-14
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

AMLODIPINE BESYLATEPrescription
AMLODIPINE BESYLATE EQ 10MG BASE · TABLET · ORAL
AMLODIPINE BESYLATEPrescription
AMLODIPINE BESYLATE EQ 2.5MG BASE · TABLET · ORAL
AMLODIPINE BESYLATEPrescription
AMLODIPINE BESYLATE EQ 5MG BASE · TABLET · ORAL

Approval history

2018-03-14Labeling · Supplement 16 · standardAP
2018-03-14Labeling · Supplement 15 · standardAP
2015-10-07Labeling · Supplement 13 · standardAP
2014-11-21Labeling · Supplement 11 · standardAP
2011-11-28Labeling · Supplement 10AP
2011-05-31Labeling · Supplement 9AP
2010-05-11Labeling · Supplement 6AP
2008-10-14Labeling · Supplement 4AP
2008-02-19Labeling · Supplement 2AP
2007-07-09OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →